Best Countries for Trials by Indication
Where the eligible patients actually are.
A country-selection framework for clinical trials — recruitment density, regulatory speed, comparator availability and cost — by indication.
"Which countries do we run this trial in — and in what mix?"
Trial geography is a strategic choice, not a CRO recommendation. Optimal mix balances recruitment speed, regulatory clock, comparator availability and cost.
Trial-country selection is a strategic decision that shapes timeline, cost and data quality. The optimal answer is rarely “wherever the CRO recommends” — it’s a portfolio optimized across recruitment density, regulatory clock and comparator availability.
What we’re seeing in the data.
Eligible-patient density beats population
High prevalence + diagnosed pool > raw country size.
Regulatory clock varies 3–9 months
Materially shifts effective trial start.
Comparator availability is a real constraint
Some active-comparator drugs are unavailable in EM.
How to think about it.
-
01
Score eligible-patient density
Diagnosed prevalence × site footprint.
-
02
Score regulatory clock
CTA approval timelines.
-
03
Score comparator access
Active arm availability.
-
04
Optimize for cost
Per-patient cost variance.
What separates a good answer from a defensible one.
Often dominates timeline.
Standards differ across geo.
Russia, China dynamics.
Where the signal comes from.
Common questions.
How many countries is optimal?
Depends on indication — onc trials often 8–15, rare disease 15–25, cardio 25+.
Are EM trials always cheaper?
Per-patient yes, but fully-loaded with regulatory and data overhead, often less of a saving than expected.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist